OR-1855
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background and aims LEVO is a novel inodilator developed to treat heart failure. Biotransformation of LEVO in the intestinal…
Levosimendan, a Ca(2+) sensitizer, has emerged as an alternative option of pharmacologic inotropic support in patients with…
OR-1896 is a pharmacologically active, long-lived metabolite of levosimendan. In the current study, the metabolism of (14)C…
Levosimendan enhances cardiac contractility primarily via Ca sensitization, and it induces vasodilation through the activation of…
Levosimendan (LEVO) enhances cardiac contractility via Ca2+ sensitization and induces vasodilation through the activation of KATP…
Levosimendan (LEVO) enhances cardiac contractility via Ca2+ sensitization and induces vasodilation through the activation of KATP…